{
    "nct_id": "NCT03127735",
    "official_title": "An Open-label, Non-randomized, Multicenter Phase I Study to Determine the Maximum Tolerated and / or Recommended Phase II Dose of Oral Mutant IDH1 (mIDH1) Inhibitor BAY1436032 and to Characterize Its Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Efficacy in Patients With mIDH1-R132X Advanced Acute Myeloid Leukemia (AML)",
    "inclusion_criteria": "* Patients with advanced AML that harbors IDH1 mutation\n* Patients are relapsed from or refractory to at least 1 previous line of therapy\n* Good kidney and liver function\n* Male or female patients\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\n* Women must have a negative serum pregnancy test within 7 days prior to the first dose of study drug or be surgically or biologically sterile or postmenopausal\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previously treated with any prior mIDH1 targeted therapy\n* Extramedullary disease only\n* History of clinically significant or active cardiac disease\n* Active clinically significant infection\n* Unresolved chronic toxicity of previous AML treatment\n* Taking known strong cytochrome P450 (CYP) 2C8 inducers or inhibitors\n* Pregnancy or breast-feeding",
    "miscellaneous_criteria": ""
}